Biodistribution and radiation dosimetry of [

Dosimetry PET PSMA Prostate cancer

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
25 Jul 2019
Historique:
received: 26 04 2019
accepted: 17 07 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 28 7 2019
Statut: epublish

Résumé

We investigated the whole-body distribution and the radiation dosimetry of [ Ten patients with prostate cancer and biochemical recurrence or radiologic evidence of metastatic diseases were examined with 329-384 MBq (mean 359 ± 17 MBq) [ Physiologic radiotracer accumulation was observed in the salivary and lacrimal glands, liver, spleen, and intestines, in a pattern resembling the distribution known from other PSMA-tracers with excretion via urinary and biliary pathways. The effective dose from [ The highest TBR of [

Identifiants

pubmed: 31346821
doi: 10.1186/s13550-019-0540-7
pii: 10.1186/s13550-019-0540-7
pmc: PMC6658635
doi:

Types de publication

Journal Article

Langues

eng

Pagination

66

Références

Prostate. 1999 Apr 1;39(1):28-35
pubmed: 10221263
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Clin Cancer Res. 2008 May 15;14(10):3036-43
pubmed: 18483369
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054
J Med Chem. 2010 Feb 25;53(4):1732-40
pubmed: 20088512
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
pubmed: 22042970
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6
pubmed: 22310854
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Appl Radiat Isot. 2013 Jun;76:55-62
pubmed: 23063597
J Nucl Med. 2012 Dec;53(12):1883-91
pubmed: 23203246
Radiat Prot Dosimetry. 2014 Dec;162(3):299-305
pubmed: 24353030
Org Biomol Chem. 2014 Oct 28;12(40):8094-9
pubmed: 25190038
J Nucl Med. 2015 Jun;56(6):855-61
pubmed: 25883128
Mol Imaging Biol. 2015 Aug;17(4):565-74
pubmed: 25896814
Mol Imaging Biol. 2015 Aug;17(4):575-84
pubmed: 26013479
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
J Med Chem. 2016 Mar 10;59(5):1761-75
pubmed: 26878194
J Nucl Med. 2017 Mar;58(3):425-431
pubmed: 27789722
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
J Nucl Med. 2017 Jun;58(6):947-952
pubmed: 27908968
J Nucl Med. 2019 Jun;60(6):817-823
pubmed: 30389823
J Pharmacol Exp Ther. 1998 Aug;286(2):1020-5
pubmed: 9694964

Auteurs

Melanie Hohberg (M)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. melanie.hohberg@uk-koeln.de.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany. melanie.hohberg@uk-koeln.de.

Carsten Kobe (C)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Philipp Krapf (P)

Institute of Neuroscience and Medicine, INM-5 (Nuclear Chemistry), Research Center Juelich GmbH, Juelich, Germany.

Philipp Täger (P)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Jochen Hammes (J)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Felix Dietlein (F)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Boris D Zlatopolskiy (BD)

Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany.

Heike Endepols (H)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany.

Markus Wild (M)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Stephan Neubauer (S)

West-German Prostate Center, Klinik am Ring, Cologne, Germany.

Axel Heidenreich (A)

Department of Urology, University Hospital of Cologne, Cologne, Germany.

Bernd Neumaier (B)

Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine, INM-5 (Nuclear Chemistry), Research Center Juelich GmbH, Juelich, Germany.

Alexander Drzezga (A)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Markus Dietlein (M)

Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Cancer Center Cologne, University Hospital of Cologne, Cologne, Germany.

Classifications MeSH